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Abstract
Background: Mechanical chest compression devices consistently deliver high-quality chest compressions. Small
very low-quality studies suggest mechanical devices may be effective as an alternative to manual chest compressions
in the treatment of adult in-hospital cardiac arrest patients. The aim of this feasibility trial is to assess the feasibility of
conducting an effectiveness trial in this patient population.
Methods: COMPRESS-RCT is a multi-centre parallel group feasibility randomised controlled trial, designed to assess the
feasibility of undertaking an effectiveness to compare the effect of mechanical chest compressions with manual chest
compressions on 30-day survival following in-hospital cardiac arrest.
Over approximately two years, 330 adult patients who sustain an in-hospital cardiac arrest and are in a non-shockable
rhythm will be randomised in a 3:1 ratio to receive ongoing treatment with a mechanical chest compression device
(LUCAS 2/3, Jolife AB/Stryker, Lund, Sweden) or continued manual chest compressions. It is intended that recruitment
will occur on a 24/7 basis by the clinical cardiac arrest team. The primary study outcome is the proportion of eligible
participants randomised in the study during site operational recruitment hours. Participants will be enrolled using a
model of deferred consent, with consent for follow-up sought from patients or their consultee in those that survive the
cardiac arrest event.
The trial will have an embedded qualitative study, in which we will conduct semi-structured interviews with hospital
staff to explore facilitators and barriers to study recruitment.
Discussion: The findings of COMPRESS-RCT will provide important information about the deliverability of an
effectiveness trial to evaluate the effect on 30-day mortality of routine use of mechanical chest compression
devices in adult in-hospital cardiac arrest patients.
Trial registration: ISRCTN38139840, date of registration 9th January 2017.
Keywords: Cardiac arrest, Cardiopulmonary resuscitation, Advanced cardiac life support, Mechanical chest
compression device
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Background
Each year, approximately 35,000 patients have a cardiac
arrest in UK hospitals, of which less than one in five
patients survives to leave hospital [1]. Observational
studies report the association between high-quality car-
diopulmonary resuscitation (CPR) and improved sur-
vival, as well as the challenge of delivering high-quality
manual CPR in clinical practice [2–5].
Mechanical chest compression devices consistently deliver
high-quality chest compressions [6]. In the out-of-hospital
setting, large, high-quality randomised controlled trials have
found no evidence of improved patient outcome in patients
treated with mechanical CPR (mech-CPR), compared
with manual CPR (man-CPR) [7–10]. In contrast, very
low-quality small randomised and observational studies
report evidence of an association between mech-CPR and
increased survival in in-hospital cardiac arrest (odds ratio
of hospital/30-day survival 2.34, 95% confidence interval
1.42 to 3.85) [11].
This apparent discrepancy in findings between the
in-hospital and out-of-hospital setting may reflect differ-
ences in evidence quality or clinical factors, such that
mech-CPR is more effective than man-CPR in the hos-
pital setting [12, 13]. Examples of such factors include
opportunity for early optimal device deployment by a
clinical team with frequent cardiac arrest exposure and
the challenge of delivering effective manual chest com-
pressions on a hospital bed, due to the compressibility of
the underlying mattress [2, 14, 15].
Based on this ongoing uncertainty, there is a need
for a clinical trial to evaluate the effect of the routine
use of mech-CPR, compared with man-CPR, on
30-day survival in adults that sustain an in-hospital
cardiac arrest. However, such a trial would require a
large sample size and might be beset by a number of
practical challenges, such that is prudent to first
undertake a feasibility trial.
Methods/design
COMPRESS-RCT is a multi-centre parallel group
feasibility randomised controlled trial, in which adult
patients that sustain a non-shockable in-hospital car-
diac arrest are randomised in a 3:1 ratio to receive ei-
ther mech-CPR or ongoing man-CPR (Fig. 1). The
aim of the trial is to assess whether it is feasible to
undertake an effectiveness trial to examine the effect
of the use of mech-CPR on 30-day survival following
in-hospital cardiac arrest. A qualitative study is em-
bedded in the trial, in which semi-structured inter-
views are conducted with clinicians involved in the
trial to explore potential facilitators and barriers to
recruitment. The trial flow diagram is presented in
figure one.
Trial approvals and conduct
COMPRESS-RCT is approved by the West Midlands –
Coventry and Warwickshire National Health Service
Research Ethics Committee (16/WM/0299). The Health
Research Authority Confidentiality Advisory Group has
approved the processing and transfer of data without
consent, under The Health Service (Control of Patient
Information) Regulations 2002 (16/CAG/0088). The
trial is registered with the ISRCTN Trial Registry
(ISRCTN08233942). The trial is funded by a National
Institute for Health Research Post-Doctoral Research
Fellowship (PDF-2015-08-109).
The trial is conducted in accordance with the Medical
Research Council (MRC) guidelines on Good Clinical
Practice, applicable UK legislation and the Warwick
University Clinical Trials Unit Standard Operating Proce-
dures. The trial sponsor is the University of Warwick.
The study is co-ordinated by Warwick Clinical Trials
Unit. It is run in collaboration with five English acute
hospital research sites: Heartlands Hospital, University
Hospitals Birmingham NHS Foundation Trust; University
Hospital, University Hospitals Coventry and Warwickshire
NHS Trust; Warwick Hospital, South Warwickshire NHS
Foundation Trust; Sandwell General Hospital, Sandwell
and West Birmingham Hospitals NHS Trust; and
Blackpool Victoria Hospital, Blackpool Teaching Hospitals
NHS Foundation Trust.
Fig. 1 Trial flow diagram
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Outcome measures
The primary outcome for this feasibility trial is the pro-
portion of eligible patients randomised during site oper-
ational recruitment hours.
We will measure a range of secondary outcome mea-
sures, grouped as study feasibility outcomes, patient out-
comes, process outcomes, and safety outcomes, which
are summarised in Table 1.
Eligibility criteria
Participants are eligible to be included in the trial if
they:
1. Sustain an in-hospital cardiac arrest and resuscitation
is attempted by a hospital cardiac arrest team trained
in the use of the mechanical chest compression
device (excludes cardiac arrests in the emergency
department).
2. In a non-shockable rhythm (pulseless electrical
activity or asystole) at the time of eligibility
assessment.
3. Known or believed to be aged 18 years or over.
A team is categorised as being trained in device use if
at least two clinicians present have been trained in
device use.
Exclusion criteria are:
1. Patient has valid do not attempt cardiopulmonary
resuscitation order.
2. Known or clinically apparent pregnancy.
3. Cardiac arrest where use of a mechanical chest
compression device is contra-indicated (e.g. following
cardiac surgery, thoracic trauma, patient size).
4. Known previous study participation.
5. Patient requiring use of mechanical chest
compression device as part of routine clinical care.
6. Patient known to be detained by Her Majesty’s
Prison Service.
Recruitment and randomisation
It is intended that, where possible, the recruitment process
is led 24-h a day by the hospital cardiac arrest team. On
arrival of the mechanical device at the cardiac arrest loca-
tion, a trained member of the cardiac arrest team assesses
patient eligibility for study inclusion. If a patient is
identified as being eligible, then the patient proceeds
to randomisation.
Patients are individually randomised in a 3:1 ratio in
favour of the use of the mech-CPR, using a sequentially
numbered sealed opaque envelope system. An unequal
randomisation ratio was chosen to increase clinician ex-
posure to device use during the trial. A single envelope
is stored with each mechanical device at all times. The
randomisation sequence was created by the study statisti-
cian, using the centre as strata and using random blocks
to ensure that a 3:1 allocation was maintained for both in-
terventions for a given strata. Envelopes are packed by a
Warwick Clinical Trials Unit staff member who is inde-
pendent of the study team.
At the point that the envelope is opened, the patient is
categorised as being randomised for the intention-to-treat
analysis. Following envelope use, the next sequentially
numbered envelope is allocated to that device.
Consent
Cardiac arrest is a sudden, unpredictable event, in which
the patient immediately loses consciousness. Furthermore,
the need for immediate treatment makes it impractical to
obtain informed consent from the patient’s consultee prior
to trial enrolment. On this basis, a Research Ethics Com-
mittee has approved the initial enrolment of trial partici-
pants under a waiver of consent in accordance with the
English law.
Participants that survive the cardiac arrest are approached
at the earliest reasonable opportunity following the cardiac
arrest event. Following explanation of the trial, the partici-
pant or their consultee is offered one of three options: 1)
use of routine health data sources for data collection and
completion of questionnaires at discharge and six-months;
Table 1 Study secondary outcomes
Study feasibility outcomes (formulae detailed summary in Additional file 1)
• Proportion of patients randomised outside of weekday daytime hours).
• Device deployment time- measured as the pause in chest
compressions associated with device deployment.
• Proportion of patients/consultees providing agreement to ongoing
study participation.
• Success of study blinding procedures.
• Proportion of patients with complete follow-up data.
• Proportion of patients with analysable chest compression quality data.
Patient outcomes
• Return of spontaneous circulation- defined as the return of a
spontaneous circulation for at least twenty minutes.
• Duration of critical care and hospital stay.
• Survival- measured at hospital discharge, 30-days, and 6-months.
• Quality of life- measured using EQ-5D-5 L (EuroQOL- 5 dimensions- 5
levels) and SF-12 (12-item short form survey) questionnaires at hospital
discharge and 6-months.
• Good neurological outcome measured using cerebral performance
category (CPC) at discharge and the modified Rankin score (mRS) at
discharge and at six-months. Good neurological outcome will be
defined as a CPC of 1 or 2 or return to baseline (pre-admission) CPC,
or mRS of 0–3 or return to baseline (pre-admission) mRS.
Process outcomes
• Cardiopulmonary resuscitation (CPR) quality (chest compression rate,
chest compression depth, flow-fraction, pre-shock pause, post-shock
pause, peri-shock pause).
Safety outcomes
• Device related adverse events
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2) use of routine health data sources for data collection
without questionnaire completion; or 3) declination of
further study involvement and data collection. In the
event that the participant lacks capacity to make deci-
sions, this approach is made to the participant’s desig-
nated personal or professional consultee.
We consulted in detail with a group of patient re-
search ambassadors regarding the approach that should
be adopted in relation to trial information provision to
family members in the event that the participant dies.
The group carefully considered the three main options:
active information (e.g. letter); passive information (e.g.
poster in hospital bereavement office), or no information.
The patient research ambassadors recommended that fam-
ily members should not be informed about trial participa-
tion. In forming this view, the group considered factors
such as the nature of the intervention being studied and
the balance of benefit and harm in providing information at
a time of bereavement. This reflects the approach that has
been adopted in similar trials [8, 16, 17].
Sources of bias
Compliance and contamination
Compliance with allocated study treatment is being moni-
tored, together with reasons for non-compliance, through-
out the trial. It is acknowledged that non-compliance may
be unavoidable in some circumstances, such as where a
participant has return of spontaneous circulation follow-
ing randomisation and prior to initiation of mech-CPR.
Where possible, defibrillator download data is used to
corroborate compliance information recorded on the case
report form.
Potential causes of contamination are dependent on
study allocation. In the mech-CPR arm, contamination
is most likely attributable to compliance issues. In the
man-CPR arm, crossover may occur if a special circum-
stance arises following randomisation where local policy
requires use of mech-CPR (e.g. post-randomisation deci-
sion for intra-arrest coronary angiography). Such events
are likely to be rare and are recorded and monitored
throughout the trial.
Blinding
The nature of the intervention makes it impossible to
blind clinical personnel present at the cardiac arrest event.
It is not possible to blind clinical and site research teams to
treatment allocation as the intervention is recorded in the
participant’s medical record and clinical examination may
indicate device use (e.g. chest bruising). However, it is not
considered likely that knowledge of treatment allocation
will influence delivery of other intra-arrest or post-arrest
interventions.
Participants will be initially blinded as they will be un-
conscious throughout the cardiac arrest event. An active
attempt is made to maintain this blinding, although partici-
pants may nevertheless subsequently become unblinded
(e.g. if they access their medical records). The rationale for
maintaining blinding will be explained during the consent
process and in study information. The success of partici-
pant blinding is measured through study questionnaires
distributed at hospital discharge and six-months by asking
participants whether they are aware of their study allocation
and which treatment they believe that they received.
Trial interventions/treatment
All patients initially receive manual chest compressions.
Following commencement of the trial intervention, the
intervention will continue for the duration of the cardiac
arrest event. Aside from the trial intervention being tested
(method of chest compression delivery), it is expected that
all cardiac arrest interventions in both groups is de-
livered in accordance with Resuscitation Council (UK)
guidelines [18].
Mech-CPR (intervention group)
In participants randomised to the mechanical chest
compression trial arm, a LUCAS-2 or LUCAS-3 device
(Jolife AB/Stryker, Lund, Sweden) is deployed as early as
possible following randomisation. The device is used in
place of manual chest compressions as long as continued
resuscitation is indicated.
Cardiac arrest teams are trained to minimise pauses in
chest compression delivery during device deployment.
The device is deployed in two phases (1- insertion of the
back plate; 2- deployment of the upper part of the de-
vice), with chest compressions delivered between the
two phases. Teams aim for the maximum chest com-
pression pause during each phase to be less than ten
seconds. The training method being used is modelled on
our preparatory manikin work [19].
Man-CPR (control group)
In patients randomised to the man-CPR arm, patients
continue to receive manual chest compressions. Where
available, the cardiac arrest team may use a real-time au-
diovisual feedback device to guide the quality of manual
chest compressions.
Data collection and management
Study data are collected by site research teams.
Anonymised data are transferred securely to the trial
co-ordinating centre. Study data items and definitions
match, as far as possible, those used for the UK-based
National Cardiac Arrest Audit [1]. Table 2 shows an
overview of data to be collected and the corresponding
assessment time-point. In participants that consent to
follow-up, the period of follow-up is six months after
the cardiac arrest event.
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Adverse events/adverse device events
COMPRESS-RCT enrols a population of participants who
are in an immediately life-threatening situation. The major-
ity of participants are not expected to survive, and those
that do will require a prolongation of their hospital stay and
may have long-term incapacity and disability. These events
will be recorded as outcome measures. As such, adverse
events and adverse device events will only be recorded
where the event is potentially related to trial participation
(i.e. may have resulted from study treatment) and the event
is unexpected. Events are only recordable if they occur
prior to the participant being discharged from hospital.
Expedited reporting is required for recordable adverse
events and adverse device events that meet standardised
criteria for seriousness, namely events that: result in death,
are immediately life-threatening, require hospitalisation or
prolongation of existing hospitalisation, result in persistent
or significant disability or incapacity, result in congenital
abnormality or birth defect, or result in an important
medical condition.
Sample size
The planned sample size is 330 participants. This number
is based on two separate calculations.
Firstly, in relation to the primary outcome, we project
a total eligible sample size of 550 participants at study
sites over the study period. Based on a recruitment rate
of 60%, a sample size of 330 randomised patients will
allow us to estimate the 95% confidence interval of the
recruitment rate with sufficient precision (i.e. 55.9 to
64.1%) to support progression to an effectiveness trial.
Secondly, we will use the approach of comparing groups
using an 80% one-sided confidence interval, as described by
Cocks and Torgerson, to establish if a clinically meaningful
difference between groups in an effectiveness trial can be
ruled out, thereby precluding progression to an effective-
ness trial [20]. For an effectiveness trial, a sample size of
3554 patients would be required to detect a 3.5% absolute
improvement in 30-day survival at a power of 90% and a
significance level of 0.05. As such, 9% of 3554 (320) is re-
quired for our feasibility study, which has been slightly in-
creased to account for patients lost to follow-up [20].
Statistical analysis
Feasibility outcomes will be reported using descriptive
statistics. Categorical data will be described as frequency
and percentage. Continuous data will be assessed for nor-
mality, and described as mean and standard deviation or
median and interquartile range as appropriate.
We will report and analyse patient and process outcomes
as we would for an effectiveness trial. Analyses will be
undertaken on an intention-to-treat basis. For dichotomous
outcomes, we will describe differences between groups as
risk ratio and 95% confidence interval. For continuous out-
comes, we will report mean difference and 95% confidence
interval. In addition, for the outcome of 30-day survival, we
will compare groups using an 80% one-sided confidence
interval, based on the approach described by Cocks and
Torgerson [20]. We will report both unadjusted analyses,
and analyses adjusted for key baseline characteristics.
Qualitative study
The qualitative aspect of the study will be undertaken at
centres participating in the clinical trial, and will explore
staff member’s experiences of being involved in the trial,
as well as potential barriers and facilitators to recruitment.
Table 2 Schedule of intervention delivery and data collection
Assessment points 1 2 3 4 5 6
Assessment point window Cardiac arrest
event
2 days (± 3 days)
after assessment 1
Regular in-hospital
reviews
30-day (± 2 days)
after assessment 1
Hospital
discharge†
Six-months (± 1 m)
after assessment 1
Eligibility assessment ✓
Intervention ✓
Cardiac arrest event data ✓ ✓
Patient demographics/past medical
history
✓
Defibrillator record download ✓
Post-cardiac arrest treatment ✓ ✓ ✓
Length of hospital stay ✓
Survival status ✓ ✓ ✓ ✓ ✓ ✓
Quality of life (SF-12 and EQ-5D-5 L) ✓ ✓
Assessment of blinding ✓ ✓
Consent to continue‡ ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓ ✓ ✓
† −May occur before visit four; ‡ − Seek at first appropriate opportunity
SF-12- 12-item short form survey; EQ-5D-5 L- EuroQOL- 5 dimensions- 5 levels
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Following written informed consent, a researcher will con-
duct a digitally audio recorded face-to-face semi-structured
interview with the staff member about their experience
of the COMPRESS-RCT study. Staff members will be
purposively sampled to ensure a diverse sample based
on factors such as clinical role, study site, and whether
or not a patient was actually randomised to the study.
Recruitment will continue recruitment until data satur-
ation is achieved, which is anticipated to be approxi-
mately 30 participants [21, 22].
Interviews will be transcribed verbatim. Data will be
analysed using a constant comparative method that is
informed by a grounded theory approach [23]. We will
review each interview on its completion and compare it
to other interview data. This process will enable us to
identify patterns and themes within the dataset, and may
facilitate the development of a conceptual model to de-
scribe potential and actual barriers to recruitment, to-
gether with possible solutions.
Trial oversight/monitoring
The trial is managed by a trial management group that
meets on a monthly basis. The management group is
comprised of clinical co-applicants, a methodologist, ad-
ministrative staff, and patient research ambassadors. Inde-
pendent oversight is provided through a trial oversight
committee, comprised of an independent chair and trial
management group members. The oversight committee
meets on a six-monthly basis. The oversight committee
chair, trial statistician, and an independent clinical expert
review unblinded outcome data in a closed meeting fol-
lowing each oversight committee meeting.
Discussion
The time-critical nature of cardiac arrest makes research
on the effectiveness of cardiac arrest interventions both
practically and ethically challenging [24]. Observational
studies provide useful insights in to the effectiveness of
interventions, but are prone to biases, such as selection
bias and the recently described resuscitation time bias
[24, 25]. In the out-of-hospital setting, observational
studies of mech-CPR have produced inconsistent findings
[26–28]. In contrast, findings of high-quality large rando-
mised controlled trials have produced consistent results,
showing no benefit in the routine use of mech-CPR com-
pared with man-CPR [10]. Such data highlights the value
of using high-quality randomised controlled trials, where
available, as a basis for policy-making.
To date, cardiac arrest randomised controlled trials have
tended to focus on the out-of-hospital setting. A system-
atic review of cardiac arrest randomised controlled trials
published between 2002 and 2012 identified 61 trials, of
which only three (5%) included in-hospital cardiac arrest
patients [29]. Differences between out-of-hospital and
in-hospital cardiac arrest in terms of patient characteris-
tics and clinical response limit the direct generalisability
of research findings between these settings [1, 30]. Fur-
thermore, it likely means that experience and lessons
learned from the successful delivery of out-of-hospital car-
diac arrest research cannot necessarily be directly trans-
ferred to the in-hospital setting [31].
COMPRESS-RCT will provide important new informa-
tion as to the feasibility of conducting a randomised con-
trolled trial of mech-CPR in the hospital setting. More
broadly, we will provide new insight in to the challenges
of both delivering cardiac arrest research on a 24/7 basis
in an acute hospital.
Trial status
The current approved protocol is version 3.0, dated 29th
January 2018. The full protocol is included in the elec-
tronic supplement. Trial recruitment is ongoing. Trial
recruitment commenced February 2017, with a sched-
uled end date of February 2019.
Additional file
Additional file 1: Formulae for deriving study feasibility outcomes. (PDF
288 kb)
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